Division of General Internal Medicine, Johns Hopkins University School of Medicine, 10753 Falls Rd, Suite 325, Lutherville, MD 21093, USA.
J Clin Oncol. 2011 Jan 1;29(1):40-6. doi: 10.1200/JCO.2009.27.3011. Epub 2010 Nov 29.
The goal of this study was to perform a systematic review and meta-analysis to examine the effect of pre-existing diabetes on breast cancer-related outcomes.
We searched EMBASE and MEDLINE databases from inception through July 1, 2009, using search terms related to diabetes mellitus, cancer, and prognostic outcome. Studies were included if they reported a prognostic outcome by diabetes status, evaluated a cancer population, and contained original data published in the English language. We performed a meta-analysis of pre-existing diabetes and its effect on all-cause mortality in patients with breast cancer and qualitatively summarized other prognostic outcomes.
Of 8,828 titles identified, eight articles met inclusion/exclusion criteria and described outcomes in patients with breast cancer and diabetes. Pre-existing diabetes was significantly associated with all-cause mortality in six of seven studies. In a meta-analysis, patients with breast cancer and diabetes had a significantly higher all-cause mortality risk (pooled hazard ratio [HR], 1.49; 95% CI, 1.35 to 1.65) compared with their nondiabetic counterparts. Three of four studies found pre-existing diabetes to be associated with more advanced stage at presentation. Diabetes was also associated with altered regimens for breast cancer treatment and increased toxicity from chemotherapy.
Compared with their nondiabetic counterparts, patients with breast cancer and pre-existing diabetes have a greater risk of death and tend to present at later stages and receive altered treatment regimens. Studies are needed to investigate pathophysiologic interactions between diabetes and breast cancer and determine whether improvements in diabetes care can reduce mortality in patients with breast cancer.
本研究旨在进行系统评价和荟萃分析,以检验糖尿病与乳腺癌相关结局的关系。
我们检索了 EMBASE 和 MEDLINE 数据库,检索时间截至 2009 年 7 月 1 日,使用了与糖尿病、癌症和预后结果相关的检索词。如果研究报告了糖尿病状态与预后结果之间的关系,评估了癌症人群,并包含以英文发表的原始数据,则纳入研究。我们对乳腺癌患者中预先存在的糖尿病及其对全因死亡率的影响进行了荟萃分析,并对其他预后结果进行了定性总结。
在 8828 个标题中,有 8 篇文章符合纳入/排除标准,并描述了患有乳腺癌和糖尿病患者的预后。在 7 项研究中的 6 项研究中,预先存在的糖尿病与全因死亡率显著相关。荟萃分析显示,患有乳腺癌和糖尿病的患者全因死亡率明显较高(合并风险比[HR],1.49;95%置信区间[CI],1.35 至 1.65),与无糖尿病的患者相比。4 项研究中的 3 项发现预先存在的糖尿病与疾病更晚期有关。糖尿病还与乳腺癌治疗方案的改变和化疗毒性增加有关。
与无糖尿病的患者相比,患有乳腺癌和预先存在的糖尿病的患者死亡风险更高,并且往往处于较晚期,接受的治疗方案也有所改变。需要进行研究以探讨糖尿病与乳腺癌之间的病理生理相互作用,并确定改善糖尿病治疗是否可以降低乳腺癌患者的死亡率。